Showing results (51-60 of 61) with videos related to
Sort By:
Pageof 7
Multiple Sclerosis and Related Disorders|July 17, 2023
Use of follow-on fingolimod for multiple sclerosis: Analysis of effectiveness and patient reported outcomes in a real-world clinical settingBengü Altunan, Aysun Ünal, Hüsnü Efendi, et al.Multiple Sclerosis and Related Disorders|February 9, 2024
The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosisEsra Taşkıran, Murat Terzi, Elif Merve Helvacı, et al.Neuromuscular Disorders : NMD|February 4, 2018
A database for screening and registering late onset Pompe disease in TurkeyMunevver Celik Gokyigit, Hakan Ekmekci, Hacer Durmus, et al.Multiple Sclerosis and Related Disorders|June 26, 2025
Safety and Efficacy of Cladribine in Patients Discontinuing Fingolimod Due to Elevated Transaminase Levels: The FinClad StudyMeryem Tuba Sönmez, Mehmet Fatih Yetkin, Duygu Arslan Mehdiyev, et al.Noro Psikiyatri Arsivi|March 13, 2023
Clinical and Demographic Characteristics and Two-Year Efficacy and Safety Data of 508 Multiple Sclerosis Patients with Fingolimod TreatmentMurat Terzi, Elif Merve Helvacı, Sedat Şen, et al.Multiple Sclerosis and Related Disorders|February 26, 2022
The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?Sedat Sen, Asli Tuncer, Serkan Ozakbas, et al.Neurobiology of Aging|February 16, 2015
The distinct genetic pattern of ALS in Turkey and novel mutationsAslıhan Özoğuz, Özgün Uyan, Güneş Birdal, et al.Human Mutation|June 25, 2020
Revisiting the complex architecture of ALS in Turkey: Expanding genotypes, shared phenotypes, molecular networks, and a public variant databaseCeren Tunca, Tuncay Şeker, Fulya Akçimen, et al.Journal of Neuroimmunology|July 22, 2025
Comparative efficacy of rituximab versus azathioprine in the treatment of MOG antibody-associated disease (MOGAD)Sedat Şen, Murat Kürtüncü, Serkan Demir, et al.Balkan Medical Journal|June 3, 2024
Clinical, Demographic, and Radiological Characteristics of Patients Demonstrating Antibodies Against Myelin Oligodendrocyte GlycoproteinSümeyye Koç, Sedat Şen, Yüksel Terzi, et al.Pageof 7